Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

RuiYi, ArGEN-X ink license deal for monoclonal antibody
November 2012
SHARING OPTIONS:

LA JOLLA, Calif.RuiYi (formerly Anaphore) has announced the establishment of a worldwide exclusive license with ArGEN-X for the latter's preclinical anti-IL-6 monoclonal antibody ARGX- 109, currently in development as a treatment for oncology and inflammatory diseases indications. Per the terms of the agreement, ArGEN-X will receive an upfront cash fee and equity investment of an undisclosed amount, and will also be eligible for clinical, regulatory and commercialization milestone payments, as well as royalties on any products that result.
 
"ARGX-109 was carefully selected based on its physical and biologic attributes and its range of potential clinical applications in both inflammatory diseases and oncology. Furthermore, the addition of this molecule accelerates our growth as an early development-stage company in China," Paul Grayson, RuiYi president and CEO, said in a press release.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.